OncLive TV

Dr. Rini on Axitinib for Treatment of Metastatic Renal Cell Carcinoma

October 19th 2015

Brian Rini, MD, associate professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, discusses a phase Il study that examined axitinib as a second-line therapy for metastatic renal cell carcinoma.

Dr. Patricia LoRusso on Next-Generation Sequencing Benefit in Metastatic Melanoma Treatment

October 16th 2015

Patricia M. LoRusso, DO, Professor of Medicine and Associate Director of Innovative Medicine, Yale Cancer Center, discusses taking a personalized medicine approach to treat melanoma patients whose tumors do not have BRAF alterations.

Dr. Memarzadeh on Recurrence Rates in Ovarian Cancer

October 13th 2015

Sanaz Memarzadeh, MD, PhD, gynecologic oncology, obstetrics and gynecology, University of California, Los Angeles, discusses recurrence rates in ovarian cancer.

Dr. Raffit Hassan on Avelumab in Unresectable Mesothelioma

October 12th 2015

Raffit Hassan, MD, Co-Chief Thoracic and Gastrointestinal Oncology Branch, Senior Investigator Head, Thoracic and Solid Tumor Immunotherapy Section at the Center for Cancer Research, National Cancer Institute, discusses a recent phase IB trial investigating avelumab in unresectable mesothelioma.

Dr. Kumar on Defining Multiple Myeloma

October 12th 2015

Shaji Kumar, MD, professor of Medicine, Mayo Clinic, gives an overview on the expanded definition of multiple myeloma.

Rebecca Feldman on Oncogenic Role of Caveolin-1 in Breast Cancer

October 9th 2015

Rebecca Feldman, PhD, molecular science liaison/research scientist, Caris Life Sciences, discusses caveolin-1 as potentially having an oncogenic role in breast cancer.

Dr. Maha Hussain on Novel Approaches in Prostate Cancer

October 8th 2015

Dr. Montes on the Relationship of MRI Imaging Characteristics With Race

October 8th 2015

Jennifer Montes, MD, NYU Langone Medical Center, discusses a recent study that examined the relationship of magnetic resonance imaging (MRI) characteristics with race in breast cancer.

Dr. Nazha on Mutational Model to Predict Response to Hypomethylating Agents in MDS

October 7th 2015

Aziz Nazha, MD, hematologist, Leukemia Program at the Cleveland Clinic, Taussig Cancer Institute, discusses results of a mutational model to predict response to hypomethylating agents in myelodysplastic syndromes (MDS).

Dr. Mayer on Toxicities Associated With Therapies for ER+ Breast Cancer

October 6th 2015

Ingrid A. Mayer, MD, associate professor of medicine, co-leader and clinical director, Breast Cancer Research Program, medical oncologist, Vanderbilt-Ingram Cancer Center, discusses toxicities that are associated with therapies for ER-positive metastatic breast cancer.

Dr. Semrad on SPIDER Program to Understand Resistance to Therapies

October 5th 2015

Thomas J. Semrad, MD, assistant professor, co-director, Phase I Program, UC Davis Health System, discusses the Serial Patient-Derived Xenografts to Understand Cancer Therapy Resistance (SPIDER) program at UC Davis Health System, aimed at understanding patient resistance to cancer therapies.

Dr. Ferrari on LBH589 and Bicalutamide in CRPC

October 2nd 2015

Anna C. Ferrari, MD, professor, co-director, GU Research Program, Departments of Medicine (Cancer Center) and Medicine (Residency Program), discusses a study that examined the efficacy of LBH589 and bicalutamide in patients with castration-resistant prostate cancer.

Moon Chen on Disparities in Cancer Care

October 1st 2015

Moon S. Chen Jr., PhD, MPH, associate director, Population Research and Cancer Disparities, professor, UC Davis Comprehensive Cancer Center, discusses various disparities in cancer care in underserved populations.

Dr. Morris on Lymphopenia as a Predictor of Survival in CRT-Treated NSCLC

September 30th 2015

John Morris, MD, professor of Medicine, co-director, Comprehensive Lung Cancer Center, associate director, UCCI Translational Research and Director, Experimental Therapeutics, University of Cincinnatti, discusses lymphopenia as a predictor of survival in chemoradiation-treated non–small cell lung cancer.

Jason Matney on Deep Inspiration Breath Hold During Radiation Therapy for Breast Cancer

September 29th 2015

Jason Matney, PhD, clinical assistant professor, Physics and Computing Division, Department of Radiation Oncology, UNC School of Medicine, discusses a prospective assessment of deep inspiration breath hold to prevent radiation-associated cardiac perfusion defects in patients with left-sided breast cancer.

Dr. Chan on ExteNET Trial for HER2+ Breast Cancer

September 27th 2015

Arlene Chan, MD, director, Mount Hospital at Perth, discusses the ExteNET trial, which looked at neratinib as extended adjuvant therapy in patients with early-stage HER2-positive breast cancer.

Dr. Boughey on Locoregional Trials for Breast Cancer

September 27th 2015

Judy C. Boughey, MD, chair, Division of Surgery Research, Mayo Clinic, discusses locoregional clinical trials for breast cancer.

T.S. Wiley on Bio-identical Hormone Replacement Therapy for Patients With Breast Cancer

September 27th 2015

T.S. Wiley, CEO, Wiley Protocol Systems, discusses a study that examined the efficacy of biomemetic bio-identical hormone replacement therapy for patients with metastatic breast cancer.

Dr. Kapoor on Multigene Panel Testing for Patients at Risk for Breast Cancer

September 26th 2015

Nimmi S. Kapoor, MD, surgical oncologist, Breastlink Laguna Hills and Breastlink Orange, discusses the benefits and safety of multigene panel testing in patients who are at risk for hereditary breast cancer.

Dr. Szeja on Adjuvant Radiation Therapy After Lumpectomy in Elderly Patients With TNBC

September 26th 2015

Sean Szeja, MD, radiation oncologist, University of Texas Medical Branch, discusses outcomes associated with adjuvant radiation therapy following lumpectomy for elderly patients with triple-negative breast cancer.